Citations

Clear

421 citation(s) found for "Short, C".

PT6:01 Cardiovascular risk in SLE is concentrated among lupus nephritis and aPL-positive subgroups: a population-based inception cohort study
Navarro-Mendoza, Erika, Mella-Bonilla, Isabella, Flores-Gouyonnet, Jaime, Figueroa-Parra, Gabriel, El-Hasbani, Georges, Sandino-Bermúdez, Marlon J , Sánchez-Rodríguez, Alain , Hulshizer, Cassondra A., Crowson, Cynthia S, Duarte-García, Ali, Bautista-Vargas, Mario Alejandro , Flores‐Gouyonnet, Jaime , Figueroa‐Parra, Gabriel , González‐Treviño, Mariana , Hasbani, Georges El , Crowson, Cynthia S. , Duarte‐García, Alí

Mayo Clinic

Short Oral Presentations | March 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: A65-A66

10.1136/lupus-2026-el.64 Get It

Short term intensified pembrolizumab and tivozanib for high-risk renal cell carcinoma: STRIKE! (Alliance A032201).
Burbano, Gabriela Perez , Tan, Alan W.C. , Berg, S., Emamekhoo, Hamid, Zhang, T., Chen, Ronald, Rosenberg, Jonathan E., Galsky, Matthew D. , George, Daniel J., McGregor, Bradley A. , Ballman, Karla V. , Tan, Alan, Gulati, Shuchi , Emamekhoo, Hamid , Robin, Tyler P. , Chen, Ronald C. , Rosenberg, Jonathan E , George, Daniel J.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps577 Get It

TPS577 Background: Pembrolizumab (pembro) for one year following resection of localized high risk clear cell renal cell carcinoma (ccRCC) in a phase 3 trial resulted in improvement in relapse-free survival and overall survival (Choueiri, NEJM 2024). However, 20% of patients still experienced a relapse within 2 years with no biomarker yet identified to predict who will respond to or needs adjuvant therapy. Addition of a tyrosine kinase inhibitor (TKI) to immunotherapy (IO) is a standard of care in metastatic ccRCC, but to date no studies have addressed the addition of a TKI to IO in the adjuvant setting. Subsequently, phase 3 STRIKE! was developed to explore the benefit of 6 months of tivozanib (tivo) added to pembro vs pembro alone in the adjuvant setting for resected high risk ccRCC. Methods: Eligible patients have an ECOG performance status ≤2 and a histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features after complete resection of the primary tumor, with pathology revealing pT2 grade 4 disease or any grade ≥ T3 or TxN1. Patients are also eligible if they developed metastasis within a year after resection and then underwent resection, definitive radiation or ablation of solid, isolated, soft tissue metastases (excluding brain and bone lesions) with no evidence of active disease (M1NED). Patients will be randomized 1:1 to intravenous pembro for 48 weeks with or without the addition of tivo 1.34 mg by mouth daily D1-21 q28D for 6 months stratified by stage (T2T3 vs T4/N1 vs M1NED) . With no limit on dose holds or interruptions of tivo, dose reductions of tivo to 0.89 mg D1-21 q28D or tivo 0.89 mg every other day are allowed. No dose reductions of pembro are permitted. Following baseline imaging to confirm no disease, imaging is performed every 12 weeks for first year, every 16 weeks for second year, every 24 weeks for third year and then annually until 5 years after registration or progression. The primary endpoint will be disease-free survival (DFS) as assessed by investigator, with secondary endpoints being overall survival, safety and tolerability. The study will enroll 1040 patients to detect a minimum detectable hazard ratio of 0.67 (24-month DFS 84% in experimental arm) with 90% power. Quality of life analysis will compare global quality of life and fatigue between the two arms. Imaging and specimens will be banked for future research. The study opened to accrual in April 2025 and at this time 106 patients have enrolled. Clinical trial information: NCT06661720 .
Dynamic investigator initiated enterprise (DIVINE) in prostate cancer: Randomized phase II trial of stereotactic body radiotherapy with or without short-course androgen deprivation and AR pathway inhibition in oligometastatic castration-sensitive prostate
Zarka, Jabra , Becker, Nicole A. , Gicobi, Joanina K. , Tabiim, Anthony, Heath, Elisabeth I. , Sartor, Alton Oliver, Park, Sean Sunghun, Ager, Casey, Andrews, Jack R. , Kase, Adam M. , YU, NATHAN Y., Vargas, C., Chaudhuri, Aadel A., Kim, Yohan, Cheville, John C. , Orme, Jacob J. , Tabiim, Anthony Jagri , Zarka, Jabra G , Tabiim, Anthony , Jang, Albert , Lucien, Fabrice , Childs, Daniel S. , Ager, Casey R. , Ballman, Karla V. , Chaudhuri, Aadel A.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2026 | Volume: 44 | Issue: 7_suppl | Pages: No page available

10.1200/jco.2026.44.7_suppl.tps283 Get It

TPS283 Background: Emerging evidence suggests that metastasis-directed therapy (MDT) with stereotactic body radiotherapy (SBRT) can delay systemic therapy in oligometastatic castration-sensitive prostate cancer (omCSPC). However, the optimal timing of androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) initiation in this setting remains undefined. While deferred ADT following MDT may preserve quality of life, early short-course ADT/ARPI may eradicate micrometastatic disease and extend progression-free survival. Extracellular vesicles (EVs) carrying PSMA-positive prostate cancer (PC) signals and circulating tumor DNA (ctDNA) may serve as real-time biomarkers of MRD and treatment response. Methods: DIVINE [NCT06378866] is an open-label, phase II, randomized trial enrolling men with omCSPC defined by 1–5 metastases (≥1 extrapelvic) on conventional imaging (CT/MRI and bone scan) and testosterone >100 ng/dL. PSMA PET may be obtained for correlative purposes but does not determine eligibility. Participants (N = 220) are randomized 1:1 to: Arm A (Early systemic): SBRT plus 6 months of ADT + ARPI. Arm B (Deferred systemic): SBRT alone with observation, reserving systemic therapy until radiographic progression not amenable to further SBRT (mrPD). SBRT is delivered per institutional standard; repeat SBRT is allowed until lesions become non-addressable. The primary endpoint, modified radiographic progression-free survival (mrPFS), is the time from randomization to death or radiographic progression not amenable to further MDT, defined by PCWG3 (bone) and modified RECIST 1.1 (soft tissue) criteria on conventional imaging. Soft-tissue progression requires ≥ 20% increase in measurable disease or a new lesion; bone progression requires ≥ 2 new confirmed lesions. Secondary endpoints include OS, biochemical PFS, time to local and distant progression, and grade 3–5 adverse events during systemic therapy. Exploratory endpoints evaluate EV and ctDNA kinetics as MRD markers, correlation of PSMA-positive EV burden with outcomes, and duration of response after short-course ADT/ARPI. Correlative analyses will longitudinally quantify PSMA-positive EVs and ctDNA at baseline, on treatment, and at progression to define MRD dynamics and resistance patterns. The trial uses Pocock–Simon dynamic allocation by EV strata and metastatic burden to ensure balance across arms. The trial is open and actively enrolling across all Mayo Clinic sites; as of October 2025, 35 of the planned 220 patients have been accrued. Clinical trial information: NCT06378866 .
AI‐enhanced Centiloid quantification of amyloid PET images
Bourgeat, Pierrick , Fripp, Jurgen, Lebrat, Léo , Xia, Ying, Zisis, Georgios , Goyal, Manu S., Tosun, Duygu, Benzinger, Tammie LS., Breakspear, Michael J, Short, Cathy, Adam, Robert , Robertson, Joanne, Sperling, Reisa, O'Bryant, Sid E., Johnson, Sterling C., Jr, Clifford R. Jack, Schwarz, Christopher G., Barkhof, Frederik, Farrar, Gill , Bollack, Ariane, Collij, Lyduine E., Landau, Susan, Koeppe, Robert, Initiative, for the Alzheimer's Disease Neuroimaging, OASIS3, Team, the A4/LEARN Study, Team, The Health and Aging Brain Study (HABS‐HD) Study, WRAP, ADNI‐DOD, PISA, ADNeT, Morris, John C., Weiner, Michael W., Villemagne, Victor L., Masters, Colin L., Rowe, Christopher C., Doré, Vincent , Barkhof, Frederik , Bourgeat, Pierrick , Xia, Ying , Barkhof, Frederik , Xia, Ying , Doré, Vincent , Fripp, Jürgen , Xia, Ying, Feizpour, Azadeh , Cox, Timothy O. , Gillman, Ashley , Goyal, Manu S. , Benzinger, Tammie L.S. , LaMontagne, Pamela , Breakspear, Michael J , Lupton, Michelle K. , Short, Cathy, Sperling, Reisa Anne , O’Bryant, Sid E. , Johnson, Sterling C. , Jack, Clifford R. , Schwarz, Christopher G. , Bollack, Ariane , Collij, Lyduine , Landau, Susan , Koeppe, Robert A. , Initiative, for the Alzheimer’s Disease Neuroimaging, Morris, John C. , Weiner, Michael W. , Villemagne, Victor L. , Masters, Colin L. , Rowe, Christopher Cleon

Mayo Clinic

Alzheimer's & Dementia | February 11, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71162 | PMID 41670187 Get It

Abstract INTRODUCTION The Centiloid scale is the standard for amyloid (Aβ) PET quantification in research and clinical settings. However, variability between tracers and scanners remains a challenge. METHODS This study introduces DeepSUVR, a deep learning method to correct Centiloid quantification, by penalizing implausible longitudinal trajectories during training. The model was trained using data from 2,129 participants (7,149 Aβ positron emission tomography [PET] scans) in the Australian Imaging, Biomarkers and Lifestyle Study of ageing (AIBL)/Alzheimer's Disease Neuroimaging Initiative (ADNI) and validated using 15,807 Aβ PET scans from 10,543 participants across 10 external datasets. RESULTS DeepSUVR increased correlation between tracers, and reduced variability in the Aß‐negatives. It showed significantly stronger association with cognition, visual reads, neuropathology, and increased longitudinal consistency between studies. DeepSUVR also increased the effect size for detecting small treatment related slowing of amyloid accumulation in the A4 study. DISCUSSION DeepSUVR substantially advances Aβ PET quantification, outperforming all standard approaches, which is particularly important for clinical decision making and to detect subtle or early changes in Aβ. Highlights Novel artificial intelligence (AI)‐method that penalizes biologically implausible longitudinal trajectories, enabling the model to learn standardized uptake value ratios (SUVR) correction factors without requiring longitudinal data at inference time. Improves Centiloid consistency across tracers and studies, significantly enhancing cross‐sectional and longitudinal amyloid positron emission tomography (PET) quantification. DeepSUVR‐derived Centiloids show stronger associations with cognition, visual reads, and neuropathology. Longitudinal variability is reduced three‐ to five‐fold, enabling more reliable tracking of amyloid accumulation and better detection of treatment effects. Novel reference and target masks derived from DeepSUVR replicate most of the model's performance, offering a practical alternative for integration into existing pipelines.
The effect of low- and high-mean arterial pressure levels on short-term mortality in cardiac arrest and cardiogenic shock due to acute myocardial infarction: a meta-analysis
Berg, S Ten, Bogerd, M, Peters, E J, Ameloot, K, Russo, J J, Jentzer, J C, Kjaergaard, J, Meyer, M A S, Skrifvars, M B, Roberts, B W, Engstrom, A E, Vlaar, A P J, Otterspoor, L C, Henriques, J P S, Berg, Sanne ten , Bogerd, Margriet , Ameloot, Koen , Grand, Johannes , Russo, J.J., Jentzer, Jacob C. , Kjærgaard, Jesper , Meyer, M A S, Skrifvars, Markus B. , Engstrom, Annemarie E, Vlaar, Alexander P. J. , Otterspoor, L C, Henriques, José P S

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.2251 Get It

Abstract Background/Introduction Optimal mean arterial pressure (MAP) in patients with acute myocardial infarction related out-of-hospital cardiac arrest (AMI-OHCA) and cardiogenic shock (AMI-CS) remains unclear. Randomized controlled trials (RCTs) comparing MAP targets have been performed in OHCA patients with presumed cardiac cause, but did not provide answers to the important question what MAP target would be optimal for the AMI-OHCA population. To our knowledge, no RCTs comparing MAP targets in AMI-CS patients have been performed. Purpose This comprehensive systematic review and meta-analysis aimed to evaluate the effect of low- and high-MAP levels on short-term mortality in AMI-OHCA and AMI-CS patients. Methods We conducted a systematic search of MEDLINE (OVID), EMBASE (OVID), CINAHL (Ebsco) and Cochrane CENTRAL databases. Eligible studies reported outcomes for AMI-OHCA or AMI-CS patients for at least two groups of different average MAP levels. Both RCTs and observational studies were eligible to ensure comprehensive data collection. Authors were proactively contacted for supplementary AMI data. Random-effects models were used to pool data. Results Of 7,728 screened studies, 57 were assessed for eligibility, and 11 were included in the final analysis (4 RCTs and 7 observational studies), encompassing 3,846 patients. The primary analysis included 1,251 AMI-OHCA patients. In the AMI-OHCA patients, no significant difference in short-term mortality was observed between low- and high-MAP groups in RCT (34.9% vs. 39.4%, RR 0.88, 95%-CI 0.70-1.10), observational-, and combined data. As only one of the 11 included studies reported on separate AMI-CS data, no meta-analyses of solely AMI-CS patients could be performed. Conclusions Our meta-analysis showed no significant difference in short-term mortality between low- and high-MAP levels in AMI-OHCA patients. Only one study in selected AMI-CS patients without OHCA patients was available. This highlights the importance of identifying tailored MAP strategies in both AMI-OHCA and AMI-CS patients.Flow chart of the selection of studies Short term mortality – AMI-OHCA patients
High-power short-duration ablation versus conventional power ablation in pulmonary vein isolation of atrial fibrillation patients: a systematic review and meta-analysis of randomized controlled trials
Cabral, D Curi Barbosa Izoton, Rivera, A , Braga, M, Passos, B Mariz Ferreira, Felix, I Ferreira, Ternes, C, Brigido, A Regia Dantas, Carvalho, G Dagostin De, Deshmukh, A, Desimone, C, Cabral, David C. B. I. , Braga, M, Passos, Bárbara Mariz Ferreira, Félix, Iuri Ferreira , Ternes, Caique M. P. , Brígido, Alexandra Régia Dantas , Carvalho, G Dagostin De, Deshmukh, Abhishek , DeSimone, Christopher V.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.814 Get It

Abstract Introduction High-power short-duration (HPSD) ablation has emerged as a promising alternative to conventional power delivery (CPD) for pulmonary vein isolation (PVI) among patients with atrial fibrillation (AF). However, its efficacy, procedural efficiency, and safety profile remain uncertain. Methods PubMed, Embase, Cochrane Library and ClinicalTrials.Gov databases were systematically searched for randomized controlled trials (RCTs) comparing HPSD with CPD ablation for PVI in patients with AF. Random-effects models were used to pool hazard ratios (HR) and risk ratios (RR) with 95% confidence intervals (CI). Results Seven RCTs with 1,006 patients (514 HPSD, 489 CPD) were included. No significant differences were found in freedom from arrhythmia during the follow-up period (HR 0.77; 95% CI 0.41–1.45; p=0.424). AF recurrence did not differ (RR 0.94; 95% CI 0.65–1.36; p=0.733) between groups. HPSD had a significantly shorter procedural (MD -22.61 min; 95% CI -33.18, -12.04; p<0.001) and RF ablation (MD -15.70 min; 95% CI -20.86, -10.55; p<0.001) times, with comparable fluoroscopy time (MD 0 min; 95% CI -0.44, 0.45; p=0.99) between groups. Conclusion In patients with AF undergoing PVI, HPSD did not increase freedom from arrhythmia as compared with CPD ablation, however it was associated with shorter procedure and RF ablation times. These findings suggest that HPSD may be a more efficient approach without compromising clinical outcomes.
Gene therapy for short QT syndrome type 1 (SQT1): a proof-of-concept efficacy trial in transgenic SQT1 rabbits
Bains, S, Alerni, N, Oerdoeg, B, Horváth, András , Louradour, Julien , Giammarino, L, Tester, D J, Beslac, Olgica, Christoforou, Nicolas , Brunner, Michael, Casoni, Daniela , Brooks, G, Ackerman, M J, Odening, K E, Nimani, Saranda , Bains, Sahej , Alerni, Nicolò , Ördög, Balázs , Horvath, A, Giammarino, Lucilla , Tester, David J. , Brooks, Gabriel , Odening, Katja E.

Mayo Clinic

European Heart Journal | February 4, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.4640 Get It

Abstract Background Short QT syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in the KCNH2-encoded Kv11.1 potassium channel, responsible for the repolarising IKr current. These variants lead to pathologically shortened cardiac repolarisation and QT intervals on 12-lead ECG, predisposing patients to life-threatening ventricular arrhythmias and sudden cardiac death. Purpose To investigate the therapeutic efficacy of our KCNH2-specific suppression-replacement gene therapy (KCNH2-SupRep) in transgenic SQT1 rabbits generated by cardiac-specific overexpression of KCNH2-N588K. Methods KCNH2-SupRep was developed by combining a custom-designed KCNH2 shRNA with its corresponding shRNA-immune KCNH2 cDNA, packaged into a single AAV9 vector and delivered directly into the aortic root via a Swan Ganz catheter (1E10 vg/kg). Therapeutic efficacy was evaluated in vivo by 12-lead ECG recordings pre- and three weeks post-therapy, ex vivo by optical voltage mapping, and at the cellular level by patch-clamp, calcium imaging, and qPCR in ventricular cardiomyocytes (VCMs) isolated from adult transgenic SQT1 and wild-type (WT) rabbits. Results In vivo, KCNH2-SupRep normalized the heart-rate corrected QT interval (QTc) in transgenic SQT1 rabbits towards WT levels (baseline-SQT1: 153±4ms vs SupRep-SQT1: 167±5ms, p=0.0002; Fig. 1A), without adversely impacting repolarisation heterogeneity. No such QTc changes were observed in sham-treated SQT1 rabbits (sham-SQT1) (baseline-SQT1: 155±4ms vs sham-SQT1: 146±5ms, p=0.1422). Ex vivo, at a 2.5Hz stimulation frequency, KCNH2-SupRep therapeutically prolonged the APD90 in SupRep-SQT1 hearts (176±4ms) near WT levels (179±4ms), compared to untreated (UT)-SQT1 (154±4), and resolved the pathologically increased apicobasal APD90 heterogeneity observed in UT-SQT1 hearts, supporting an anti-arrhythmic effect of KCNH2-SupRep (Fig. 1B). At the cellular level, at a 1Hz stimulation frequency, KCNH2-SupRep prolonged the APD90 in VCMs isolated from SupRep-SQT1 rabbits (363±11ms) closer to WT levels (404±14ms) as compared to UT- (314±12ms) and sham-SQT1 (322±11ms; Fig. 1C). Moreover, KCNH2-SupRep restored the cellular surrogate of the electro-mechanical window (cEMW, Ca2+ transient duration – APD) and normalized IKr in nearly 50% of VCMs (Fig. 1D), in line with a 50-60% suppression of the mutant KCNH2 transcript. This partial therapeutic effect on IKr may explain the incomplete APD90 normalization in individual VCMs. Nonetheless, both in vivo and ex vivo, this partial therapeutic effect was sufficient to completely restore the electrical properties. Conclusion This proof-of-concept study is the first to demonstrate the efficacy of gene therapy in treating SQT1 in a medium-sized animal model. KCNH2-SupRep rescued the disease phenotype in vivo, ex vivo and at cellular levels in transgenic SQT1 rabbits.Therapeutic efficacy of KCNH2-SupRep
Incorporation of Genomic Determinants Improves Diagnostic Accuracy of Oligomonocytic Chronic Myelomonocytic Leukemia
Montalban-Bravo, Guillermo, Wu, Chong , Rodríguez‐Sevilla, Juan José , Wei, Yue , Chien, K., Bouligny, Ian , Kanagal‐Shamanna, Rashmi , Li, Ziyi , Natu, Anuya , Bazinet, Alexandre , Hammond, Danielle E., Bataller, Alex, Borthakur, Gautam, Short, Nicholas J., DiNardo, Courtney D., Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Pemmaraju, Naveen, Jabbour, Elias, Issa, Ghayas C., Wang, Sa A., Patel, Keyur P. , Tang, Guilin, Medeiros, L. Jeffrey, Finke, Christy M. , Al‐Kali, Aref , Alkhateeb, Hassan, Gangat, Naseema, Mangaonkar, Abhishek A., Román, David , Arenillas, Leonor , Tefferi, Ayalew, Kantarjian, Hagop M., Garcia-Manero, Guillermo, Calvo, Xavier , Patnaik, Mrinal M. , Loghavi, Sanam, Kantarjian, Hagop M. , Bravo, Guillermo Montalban , Chien, Kelly , Gurney, Mark , Bazinet, Alexandre , Hammond, Danielle , Bataller, Alex , Borthakur, Gautam , Short, Nicholas , DiNardo, Courtney , Kadia, Tapan M , Ravandi, Farhad , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Issa, Ghayas , Wang, Sa A , Patel, Keyur P , Tang, Guilin , Medeiros, L Jeffrey , Lasho, Terra L , Finke, Christy M , Al-Kali, Aref , Csizmar, Clifford , Alkhateeb, Hassan B , Gangat, Naseema , Mangaonkar, Abhishek A. , Roman-Bravo, David , Arenillas, Leonor , Tefferi, Ayalew , Kantarjian, Hagop , Garcia-Manero, Guillermo , Calvo, Xavier , Patnaik, Mrinal , Loghavi, Sanam , Kanagal-Shamanna, Rashmi , Rodríguez-Sevilla, Juan José , Montalban‐Bravo, Guillermo , Chien, Kelly S. , Gurney, Mark E. , Hammond, Danielle , Borthakur, Gautam , Short, Nicholas J. , DiNardo, Courtney D. , Kadia, Tapan M. , Daver, Naval , Pemmaraju, Naveen , Jabbour, Elias , Wang, Sa A. , Tang, Guilin , Medeiros, L. Jeffrey , Lasho, Terra L. , Csizmar, Clifford M. , Alkhateeb, Hassan B. , Gangat, Naseema , Mangaonkar, Abhishek A. , Tefferi, Ayalew , Garcia‐Manero, Guillermo , Loghavi, Sanam

Mayo Clinic

Blood Cancer Discovery | January 26, 2026 | Volume: 7 | Issue: 3 | Pages: 414-430

10.1158/2643-3230.bcd-25-0264 | PMID 41587375 Get It

Abstract Recent updates to monocyte count thresholds recognize oligomonocytic chronic myelomonocytic leukemia (OM-CMML) as an early form of CMML. However, the clinical validity of these changes remains uncertain without incorporating biological and genomic factors. In this study, we analyzed a cohort of 911 patients (249 with OM-CMML, 359 with overt CMML, and 303 with myelodysplastic syndromes) using unsupervised clustering to evaluate the role of genomic determinants in refining CMML diagnosis. Our findings show that CMML molecular signatures (biallelic TET2 mutations or SRSF2-TET2 comutations) are linked to a distinct transcriptome, monocytic bias, classical monocytosis, and a higher risk of progression to overt CMML in OM-CMML cases. We developed a weighted genomic model and diagnostic workflow showing that combining genomic signatures with bone marrow monocyte frequencies in OM-CMML more accurately predicts progression to overt CMML. These findings support integrating genomic determinants and our clinic-ready diagnostic workflow into the CMML diagnostic framework to improve accuracy. Significance: Through comprehensive clinical and genomic profiling of a large patient cohort, alongside immunophenotypic and transcriptional cellular analyses, this study provides evidence that incorporating genomic determinants into the diagnostic criteria for OM-CMML improves diagnostic accuracy and refines the identification of early-stage CMML, thereby preventing misclassification.
Ultrasound Depiction of the Optimal Window for Needle Placement for Electromyography of the Short Head of the Biceps Femoris
Hass, Reece M. , Mitchell, C., Meiling, James B. , Litchy, William J. , Boon, Andrea J. , Hass, Reece M. , Mitchell, Cecilia V , Meiling, James B

Mayo Clinic

Muscle & Nerve | January 19, 2026 | Volume: 73 | Issue: 4 | Pages: 630-634

10.1002/mus.70154 | PMID 41553101 Get It

ABSTRACT Introduction/Aims Accurate needle electromyography (EMG) of the short head of the biceps femoris (SHBF) is often important to localize nerve damage when proximal to the fibular head. Techniques have been proposed for accurate SHBF EMG; however, needle placement accuracy is low and with the risk of inadvertent needle placement into the long head (LHBF) potentially resulting in false localization and inappropriate operative management. This study aimed to define the optimal window for accurate SHBF needle EMG placement through ultrasound (US) investigation of the anatomical relationships of the SHBF, LHBF, and common fibular nerve (CFN) in the distal posterolateral thigh. Methods Forty lower limbs from 20 healthy adults were evaluated using US. Distances from the popliteal crease (PC) to the SHBF and LHBF myotendinous junctions and position of the CFN in the popliteal fossa were recorded. The “SHBF window” was defined as the region where the SHBF muscle body is present in the absence of the LHBF. Results The SHBF was located anterolateral to the LHBF tendon/muscle and the CFN medial to the SHBF in all limbs. The average distances from the PC to SHBF and LHBF muscles were 0.6 and 6.4 cm, respectively. The optimal “SHBF window” was identified to be 3–4 cm (2–3 fingerbreadths) proximal to the PC, anterolateral to the LHBF tendon in the distal thigh. Discussion SHBF examination within this optimized window results in increased accuracy of needle placement, aiding in the electrodiagnostic localization of fibular nerve lesions.
Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.
Anyeti-Anum, Grace Patrice, Ortiz, Belisario A, Hartman, Robert P. , Harmsen, William S. , Hallemeier, Christopher L. , Krishan, Jethwa, Yoon, Harry H. , Jin, Zhaoui, Zhu, Mojun , Reisenauer, Janani , Cassivi, Stephen David, Wigle, D., Tapias, Luís Felipe, Santore, Lee Ann , Chaar, Mohamad K. Abou , Anyetei-Anum, Grace Patrice , Hallemeier, Christopher Leigh , Puig, Carlos A. , Cassivi, Stephen D. , Shen, Robert K. , Wigle, Dennis A.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 334-334

10.1200/jco.2026.44.2_suppl.334 Get It

334 Background: Sarcopenia, or decreased skeletal muscle mass, has been associated with worse surgical and oncologic outcomes across multiple malignancies. This study investigates the impact of sarcopenia on outcomes after multimodal therapy for esophageal cancer. Methods: Retrospective observational cohort study including adult patients who underwent neoadjuvant therapy followed by esophagectomy for primary esophageal cancer from January 2000 - December 2021. A fully automated abdominal segmentation using deep convolutional neural network was utilized to calculate skeletal muscle index (SMI) from preoperative CT scans performed at our institution. Males with SMI <52.4 cm 2 /m 2 and females with SMI <38.5 cm 2 /m 2 at any point before surgery were classified as sarcopenic. The relationship between sarcopenia and patient demographics, operative details, and complications were explored using chi-square tests. The relationship between sarcopenia and disease-free survival and overall survival were investigated using parsimonious multivariable analysis retaining variables with p-value <0.05 using backward selection method. Results: We identified 200 patients meeting the study criteria with 142 (71%) having sarcopenia at any time prior to surgery. Patients with sarcopenia were significantly older [65.2 (59.6, 71.2) vs 63 (53.6, 67.5), p = .023] and more likely to have had open surgery [129 (90.8%) vs 46 (79.3%), p = .034]. There were no significant differences in sex, history of diabetes, coronary artery disease, renal disease, smoking, cancer type, cancer stage, tumor size, tumor location, or margin status between sarcopenic groups ( p > .05). Sarcopenic patients were significantly more likely to require blood transfusion ≥3 units after esophagectomy [79 (55.6%) vs 8 (13.8%), p < .001] or to experience complications requiring surgical intervention [36 (24.6%) vs 7 (12.1%), p = .048]. Multivariate analysis revealed that sarcopenia was associated with disease-free and overall survival (Table). Conclusions: Sarcopenia is a prognostic factor in patients undergoing multimodal therapy for esophageal cancer. Interventions that aim to prevent decreases in SMI after initiating neoadjuvant therapy should be investigated. Multivariate analysis with sarcopenia predicting outcomes. Disease free survivalHR (95% CI) p-value Overall survivalHR (95% CI) p-value Age 1.04 (1.02, 1.06) < .001 1.04 (1.02, 1.07) < .001 Epicenter Middle Upper 1.88 (1.21, 2.86)3.16 (1.67, 5.98) .001.005< .001 1.96 (1.26, 3.04)4.00 (1.90, 8.44) < .001.003< .001 Stage Stage II Stage III Stage IV 1.88 (0.95, 3.71)2.90 (1.46, 5.75)16.02 (6.12, 41.93) < .001.069.002< .001 1.65 (0.83, 3.25)2.76 (1.37, 5.55)10.14 (4.03, 25.53) < .001.151.005< .001 Cancer type - - 1.76 (1.03, 3.02) .039 Transfusion > 3 pRBC - - 1.54 (0.99, 2.40) .057 BMI prior to cancer diagnosis - - 0.98 (0.94, 1.01 .208 Sarcopenic 1.76 (1.16, 2.67) .007 1.64 (1.04, 2.60) .033